Clostridium difficile infection in the twenty-first century
Open Access
- 25 January 2013
- journal article
- review article
- Published by Taylor & Francis in Emerging Microbes & Infections
- Vol. 2 (1) , 1-8
Abstract
Clostridium difficile is a spore-forming gram-positive bacillus, and the leading cause of antibiotic-associated nosocomial diarrhea and colitis in the industrialized world. With the emergence of a hypervirulent strain of C. difficile (BI/NAP1/027), the epidemiology of C. difficile infection has rapidly changed in the last decade. C. difficile infection, once thought to be an easy to treat bacterial infection, has evolved into an epidemic that is associated with a high rate of mortality, causing disease in patients thought to be low-risk. In this review, we discuss the changing face of C .difficile infection and the novel treatment and prevention strategies needed to halt this ever growing epidemic.Keywords
This publication has 121 references indexed in Scilit:
- A novel approach to generate a recombinant toxoid vaccine against Clostridium difficileMicrobiology, 2013
- Current Status of Clostridium difficile Infection EpidemiologyClinical Infectious Diseases, 2012
- The human microbiome: at the interface of health and diseaseNature Reviews Genetics, 2012
- The Epidemiology of Community-Acquired Clostridium difficile Infection: A Population-Based StudyAmerican Journal of Gastroenterology, 2012
- Killing kinetics of fidaxomicin and its major metabolite, OP-1118, against Clostridium difficileJournal of Medical Microbiology, 2011
- The dlt operon confers resistance to cationic antimicrobial peptides in Clostridium difficileMicrobiology, 2011
- The potential value of Clostridium difficile vaccine: An economic computer simulation modelVaccine, 2010
- Toxin B is essential for virulence of Clostridium difficileNature, 2009
- High Frequency of Rifampin Resistance Identified in an EpidemicClostridium difficileClone from a Large Teaching HospitalClinical Infectious Diseases, 2009
- Open-label, dose escalation phase I study in healthy volunteers to evaluate the safety and pharmacokinetics of a human monoclonal antibody to Clostridium difficile toxin AVaccine, 2008